Sharon Mates - Oct 14, 2021 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
Chairman, President & CEO, Director
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Stock symbol
ITCI
Transactions as of
Oct 14, 2021
Transactions value $
-$1,996,947
Form type
4
Date filed
10/18/2021, 06:00 PM
Previous filing
Aug 24, 2021
Next filing
Jan 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Sale -$56.6K -1.42K -0.12% $40.00 1.14M Oct 14, 2021 Direct F1
transaction ITCI Common Stock Sale -$1.62M -40.4K -3.54% $40.00 1.1M Oct 15, 2021 Direct F1
transaction ITCI Common Stock Options Exercise $3.05K +1.08K +0.1% $2.84* 1.1M Oct 15, 2021 Direct
transaction ITCI Common Stock Sale -$328K -8.19K -0.74% $40.00 1.09M Oct 18, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -1.08K -2.69% $0.00 38.9K Oct 15, 2021 Common Stock 1.08K $2.84 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 All shares underlying this option have vested.